Informações de Celcuity Inc

Mais detalhes de Celcuity Inc Empresa

Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.



Código da empresaCELC

Nome da EmpresaCelcuity Inc

Data de listagemSep 20, 2017

CEOMr. Brian F. Sullivan

Número de funcionários87

Tipo de títulosOrdinary Share

Fim do ano fiscalSep 20

Endereço16305 36th Ave N Ste 100

CidadeMINNEAPOLIS

Bolsa de valoresNASDAQ Capital Market Consolidated

PaísUnited States of America

Código postal55446-4285

Telefone17633920767

Sitehttps://www.celcuity.com/

Código da empresaCELC

Data de listagemSep 20, 2017

CEOMr. Brian F. Sullivan

Executivos da empresa Celcuity Inc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Brian F. Sullivan

Chairman of the Board, Chief Executive Officer, Co-Founder

3.13M

+3.45%

Mr. Richard J. Nigon

Independent Director

109.01K

+7.83%

Ms. Vicky Hahne, CPA

Chief Financial Officer

18.86K

+1.63%

Dr. Richard E. Buller, M.D., Ph.D.

Independent Director

7.71K

-0.64%

Dr. Polly A. Murphy, DVM, Ph.D.

Independent Director

5.00K

--

Dr. Lance G. Laing, Ph.D.

Co-Founder, Chief Science Officer, Vice President, Secretary, Director

--

Mr. David F. Dalvey

Independent Director

--

Dr. Charlotte Moser, M.D., Ph.D.

Chief Medical Officer

--

Dr. Leo T. Furcht, M.D.

Independent Director

--

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Brian F. Sullivan

Chairman of the Board, Chief Executive Officer, Co-Founder

3.13M

+3.45%

Mr. Richard J. Nigon

Independent Director

109.01K

+7.83%

Ms. Vicky Hahne, CPA

Chief Financial Officer

18.86K

+1.63%

Dr. Richard E. Buller, M.D., Ph.D.

Independent Director

7.71K

-0.64%

Dr. Polly A. Murphy, DVM, Ph.D.

Independent Director

5.00K

--

Dr. Lance G. Laing, Ph.D.

Co-Founder, Chief Science Officer, Vice President, Secretary, Director

--

Detalhamento da receita

Sem dados

Sem dados

Por Empresa

Por Região

Sem dados

Distribuição de ações

Atualizado em: dom, 31 de ago

Investidores

Tipos de investidores

Investidores

Proporção

Baker Bros. Advisors LP

18.66%

BVF Partners L.P.

8.17%

Sullivan (Brian F)

7.38%

Soleus Capital Management, L.P.

7.10%

Perceptive Advisors LLC

6.29%

Outro

52.40%

Investidores

Proporção

Baker Bros. Advisors LP

18.66%

BVF Partners L.P.

8.17%

Sullivan (Brian F)

7.38%

Soleus Capital Management, L.P.

7.10%

Perceptive Advisors LLC

6.29%

Outro

52.40%

Tipos de investidores

Investidores

Proporção

Hedge Fund

42.19%

Investment Advisor

19.98%

Individual Investor

11.21%

Investment Advisor/Hedge Fund

8.70%

Venture Capital

6.52%

Private Equity

6.33%

Research Firm

2.23%

Corporation

0.82%

Pension Fund

0.15%

Outro

1.86%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

241

36.62M

86.31%

-4.48M

2025Q2

214

35.30M

87.21%

-4.75M

2025Q1

215

36.05M

95.22%

-4.12M

2024Q4

205

35.54M

95.72%

-3.01M

2024Q3

191

34.97M

94.40%

-1.82M

2024Q2

174

33.96M

98.53%

+4.98M

2024Q1

164

26.84M

87.18%

+3.25M

2023Q4

146

21.83M

92.28%

-1.69M

2023Q3

148

21.82M

100.72%

+289.20K

2023Q2

156

20.45M

95.00%

-276.65K

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

Baker Bros. Advisors LP

7.92M

18.66%

+170.10K

+2.20%

Sep 08, 2025

BVF Partners L.P.

3.47M

8.17%

--

Jun 30, 2025

Sullivan (Brian F)

3.13M

7.38%

+104.34K

+3.45%

Sep 02, 2025

Soleus Capital Management, L.P.

3.01M

7.1%

+437.70K

+17.00%

Jun 30, 2025

Perceptive Advisors LLC

2.67M

6.29%

+1.04M

+63.52%

Jul 30, 2025

New Enterprise Associates (NEA)

2.14M

5.05%

-150.00K

-6.54%

Aug 18, 2025

The Vanguard Group, Inc.

1.67M

3.93%

-4.46K

-0.27%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

1.87M

4.4%

-157.82K

-7.79%

Jun 30, 2025

Eventide Asset Management, LLC

1.39M

3.27%

+123.77K

+9.78%

Jun 30, 2025

Laing (Lance G Ph.D.)

1.25M

2.95%

--

Mar 17, 2025

Ver Mais

ETFs Relacionados



Atualizado em: qui, 6 de nov

Nome

Proporção

iShares Genomics Immunology and Healthcare ETF

3.44%

Virtus LifeSci Biotech Clinical Trials ETF

2.84%

Invesco Dorsey Wright Healthcare Momentum ETF

2.32%

Tema Oncology ETF

1.6%

ALPS Medical Breakthroughs ETF

1.22%

Invesco Dorsey Wright SmallCap Momentum ETF

0.58%

iShares Micro-Cap ETF

0.28%

VictoryShares US Small Mid Cap Value Momentum ETF

0.17%

Vanguard US Momentum Factor ETF

0.12%

SPDR S&P Biotech ETF

0.1%

Ver Mais

iShares Genomics Immunology and Healthcare ETF

Proporção3.44%

Virtus LifeSci Biotech Clinical Trials ETF

Proporção2.84%

Invesco Dorsey Wright Healthcare Momentum ETF

Proporção2.32%

Tema Oncology ETF

Proporção1.6%

ALPS Medical Breakthroughs ETF

Proporção1.22%

Invesco Dorsey Wright SmallCap Momentum ETF

Proporção0.58%

iShares Micro-Cap ETF

Proporção0.28%

VictoryShares US Small Mid Cap Value Momentum ETF

Proporção0.17%

Vanguard US Momentum Factor ETF

Proporção0.12%

SPDR S&P Biotech ETF

Proporção0.1%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados